BIONTECH SE SPON. ADRS 1
Commented by Fabian Lorenz on November 1st, 2023 | 06:10 CET
More than 300% share price opportunity: BioNTech, Morphosys and Cardiol Therapeutics
Study results, along with acquisitions by Big Pharma, are the drivers of biotech company share prices. However, in the current challenging stock market environment, even positive data can be overlooked. But this opens up opportunities for investors with a little more staying power. Sooner or later, the information is recognized, and stock prices rise, or a pharmaceutical giant makes a move. At BioNTech, for example, the price reaction to the long-awaited news from the cancer pipeline has failed to materialize. Analysts are also cautious. Cardiol Therapeutics is a different story. The Canadians have taken on the fight against heart disease and are making significant progress in their research. The share had more than doubled to EUR 1.08 by the summer. Several analysts see the current setback as a buying opportunity. Experts are also giving the thumbs up to German biotech pioneer Morphosys.
Read
Commented by André Will-Laudien on October 26th, 2023 | 08:15 CEST
Omicron or Pirola? Biotech shows doubling opportunities again! BioNTech, Pfizer, Defence Therapeutics, MorphoSys in focus
We had ticked off the Corona pandemic long ago. But if you ask your acquaintances, you may find one or two who have recently been infected with the "Pirola" variant. The official code of the virus variant is BA.2.86, and it was first discovered in Israel. The current infections are spreading rapidly across Europe and have also reached Germany. So far, the new Omicron offshoot appears less contagious than its predecessors. The new symptoms associated with "Pirola" include skin rashes, diarrhea, changes in the mouth and tongue, itchy eyes and surprisingly, sore fingers or toes. What is going on here? It is a reason to look again at BioNTech and some other biotechs. Where are the opportunities lurking?
Read
Commented by Stefan Feulner on October 25th, 2023 | 07:20 CEST
BioNTech, Cardiol Therapeutics, Paion - Rising Attractiveness and Lots of Movement
The current geopolitical uncertainties with escalating conflicts in Ukraine and Israel, as well as fears of recession with continued high inflation, have also impacted the capital-intensive biotech sector. In the past week, the Nasdaq Biotech Index fell to its lowest level of the year. Since the beginning of the year, the loss amounts to almost 12%. This level should offer excellent entry opportunities for long-term investors, as many biotech companies are currently very well-positioned and attractively valued.
Read
Commented by Armin Schulz on October 17th, 2023 | 07:00 CEST
BioNTech, Cardiol Therapeutics, Bayer - Redefining the frontiers of medicine
The biotech and pharmaceutical sector is playing an increasingly important role in our society. This can be attributed primarily to demographic change, as people worldwide are getting older and older. As life expectancy increases, so does the prevalence of age-related diseases such as cancer and heart disease. These two disease categories place a significant burden on healthcare systems and require innovative solutions for diagnosis, treatment and prevention. After Corona, this could be where the next global blockbuster is developed. We look at three interesting candidates.
Read
Commented by Fabian Lorenz on October 5th, 2023 | 07:10 CEST
Buy biotech stocks now? BioNTech, Morphosys and Cardiol Therapeutics in check
In times of high interest rates, the wheat is separated from the chaff, even in the biotech sector. After all, young research-based companies, in particular, have a high demand for capital. But at the moment, all companies are being lumped together. This opens up clear buying opportunities because some have full coffers. BioNTech belongs to this group. Thanks to the COVID-19 vaccine, research is fully financed. The same goes for Cardiol Therapeutics. The share of the Canadians is one of the summer's high flyers, and the recent price setback offers an entry opportunity. The analysts' price target is over 300% above the current level. And what do analysts say about the German biotech veteran Morphosys? Goldman Sachs has tripled its price target.
Read
Commented by Nico Popp on September 27th, 2023 | 07:10 CEST
Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics
High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!
Read
Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST
Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets
Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.
Read
Commented by André Will-Laudien on September 11th, 2023 | 07:30 CEST
The next steps towards cannabis THC legalization are underway! Canopy, Tilray and BioNTech are taking the lead, and Cantourage Group is experiencing dynamic growth
Cannabis has been decriminalized in some countries but legalized in only a few states. In the US, cannabis is fully legalized in states such as California but outright banned in others such as Texas. While medical use is slowly catching on, the use as an intoxicant and cultivation for personal use remains controversial. Stronger momentum could be sparked by the US Department of Health and Human Services (HHS). The authorities are open to a downgrading of the degree of danger in the categorization of the US Drug Enforcement Administration (DEA). We are talking about two steps from Schedule I to Schedule III, which no longer puts THC on a par with common drugs such as heroin, ecstasy or LSD but classifies them as substances with comparatively little psychological dependence. That would be a revolutionary step. Which stocks can benefit?
Read
Commented by Stefan Feulner on September 7th, 2023 | 08:00 CEST
Biotech with tailwind - Newron Pharmaceuticals, Defence Therapeutics, BioNTech
There is a lot of activity in the biotechnology sector, even though the broadly diversified Nasdaq Biotech Index reflects this with a performance of only 1% since the beginning of the year. In addition to the increasing number of acquisitions by Big Pharma, promising technologies from second-tier companies are performing extremely well. Furthermore, the surging COVID-19 statistics are instilling hope in vaccine producers as they aim to revive their slumping sales.
Read
Commented by Armin Schulz on September 6th, 2023 | 08:00 CEST
BioNTech, Cardiol Therapeutics, Bayer - Tiger mosquitoes, and rising Corona numbers bring biotech back in focus
Corona infections are already rising, even though autumn has not even begun. Hospitals are already fearing a high burden during the winter. Gerald Gaß, the Chairman of the Board of the German Hospital Federation, advised high-risk patients, their close contacts and healthcare workers to keep their flu and COVID-19 vaccinations up to date. Due to constant stress triggered by crises and workload-related pressures, the number of heart patients have also increased in recent years. At the end of August, entire neighborhoods and streets in Paris were closed off to spray insecticides against tiger mosquitoes, which spread diseases like dengue and Zika viruses, among others. This is reason enough for us to examine three companies fighting these threats.
Read